Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2243-2262

  Chien, Chih Yen ^a,b   Tsai, Hsin Ting ^a,b   Su, Li Jen ^c   Chuang, Hui Ching ^a,b   Shiu, Li Yen ^d   Huang, Chao Cheng ^a,b   Fang, Fu Min ^a,b   Yu, Chun Chieh ^b   Su, Huei Ting ^b   Chen, Chang Han ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

Author keywords

Aurora A; CD44; ERK; HNSCC; osteopontin

Indexed keywords

AURORA A KINASE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; SMALL INTERFERING RNA; AURKA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL MOTILITY; CENTROSOME; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR INVASION; VERY ELDERLY; DNA MICROARRAY; FEMALE; GENETIC TRANSFECTION; HEAD AND NECK TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AURORA KINASE A; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84899576205     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1896     Document Type: Article

References (48)

1. Tatsuka M, Sato S, Kanda A, Miki T, Kamata N, Kitajima S, Kudo Y and Takata T. Oncogenic role of nuclear accumulated Aurora-A. Molecular carcinogenesis. 2009; 48(9):810-820.
2. Carmena M and Earnshaw WC. The cellular geography of aurora kinases. Nature reviews Molecular cell biology. 2003; 4(11):842-854.
3. Marumoto T, Zhang D and Saya H. Aurora-A - a guardian of poles. Nature reviews Cancer. 2005; 5(1):42-50.
4. Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, Baumgart A, Wagenpfeil S, Peschel C, Dechow T, Bier H and Keller U. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget. 2011; 2(8):599-609.
5. Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T, Watanabe G, Imamura M, Inazawa J and Shimada Y. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(5):1827-1834.
6. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nature genetics. 1998; 20(2):189-193.
7. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr. and Gandara DR. Aurora kinases as anticancer drug targets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(6):1639-1648.
8. Landen CN, Jr., Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR and Sood AK. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007; 13(14):4098-4104.
9. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ and Plowman GD. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. The EMBO journal. 1998; 17(11):3052-3065.
10. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H and Sen S. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(3):991-997.
11. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W and Czerniak B. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. Journal of the National Cancer Institute. 2002; 94(17):1320-1329.
12. Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S and Hung MC. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer. 2004; 100(1):12-19.
13. Hamada M, Yakushijin Y, Ohtsuka M, Kakimoto M, Yasukawa M and Fujita S. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. British journal of haematology. 2003; 121(3):439-447.
14. Ogawa E, Takenaka K, Katakura H, Adachi M, Otake Y, Toda Y, Kotani H, Manabe T, Wada H and Tanaka F. Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Annals of surgical oncology. 2008; 15(2):547-554.
15. Klein A, Reichardt W, Jung V, Zang KD, Meese E and Urbschat S. Overexpression and amplification of STK15 in human gliomas. International journal of oncology. 2004; 25(6):1789-1794.
16. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV and Cheng JQ. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(4):1420-1426.
17. Wang X, Lu N, Niu B, Chen X, Xie J and Cheng N. Overexpression of Aurora-A enhances invasion and matrix metalloproteinase-2 expression in esophageal squamous cell carcinoma cells. Molecular cancer research : MCR. 2012; 10(5):588-596.
18. Wu CC, Yu CT, Chang GC, Lai JM and Hsu SL. Aurora-A promotes gefitinib resistance via a NF-kappaB signaling pathway in p53 knockdown lung cancer cells. Biochemical and biophysical research communications. 2011; 405(2):168-172.
19. Seki A, Coppinger JA, Jang CY, Yates JR and Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 2008; 320(5883):1655-1658.
20. Wai PY and Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer metastasis reviews. 2008; 27(1):103-118.
21. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B and Kuo PC. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005; 26(4):741-751.
22. Fedarko NS, Jain A, Karadag A and Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2004; 18(6):734-736.
23. Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM and Huang CC. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral oncology. 2009; 45(9):798-802.
24. Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, Chen CH and Huang CC. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head & neck. 2008; 30(6):776-781.
25. Chen CH, Shiu LY, Su LJ, Huang CY, Huang SC, Huang CC, Yin YF, Wang WS, Tsai HT, Fang FM, Chuang WC, Kang HC and Hwang CF. FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway. Journal of translational medicine. 2012; 10:93.
26. Ogbureke KU, Weinberger PM, Looney SW, Li L and Fisher LW. Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma. Oncotarget. 2012; 3(3):286-298.
27. Hwang CF, Shiu LY, Su LJ, Yu-Fang Y, Wang WS, Huang SC, Chiu TJ, Huang CC, Zhen YY, Tsai HT, Fang FM, Huang TL and Chen CH. Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis. PloS one. 2013; 8(12):e84218.
28. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM, Tsai HT, Su LJ and Chen CH. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. The Journal of pathology. 2010; 222(4):367-379.
29. Lai JM, Huang CY and Chen CH. Using siRNA to uncover novel oncogenic signaling pathways. Methods in molecular biology. 2010; 623:231-242.
30. Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, Tsou AP, Lee YC, Lin TC, Hsu SL, Lin WJ, Huang CY and Chou CK. FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene. 2007; 26(29):4272-4283.
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6(1):1-6.
32. Tegge AN, Caldwell CW and Xu D. Pathway correlation profile of gene-gene co-expression for identifying pathway perturbation. PloS one. 2012; 7(12):e52127.
33. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL and Gaffney PM. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer research. 2004; 64(1):55-63.
34. Burum-Auensen E, De Angelis PM, Schjolberg AR, Kravik KL, Aure M and Clausen OP. Subcellular localization of the spindle proteins Aurora A, Mad2, and BUBR1 assessed by immunohistochemistry. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2007; 55(5):477-486.
35. Tong T, Zhong Y, Kong J, Dong L, Song Y, Fu M, Liu Z, Wang M, Guo L, Lu S, Wu M and Zhan Q. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(21):7304-7310.
36. Chen CH, Chuang HC, Huang CC, Fang FM, Huang HY, Tsai HT, Su LJ, Shiu LY, Leu S and Chien CY. Overexpression of Rap-1A indicates a poor prognosis for oral cavity squamous cell carcinoma and promotes tumor cell invasion via Aurora-A modulation. The American journal of pathology. 2013; 182(2):516-528.
37. Kao SY, Chen YP, Tu HF, Liu CJ, Yu AH, Wu CH and Chang KW. Nuclear STK15 expression is associated with aggressive behaviour of oral carcinoma cells in vivo and in vitro. The Journal of pathology. 2010; 222(1):99-109.
38. Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH and Liu Q. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis. 2008; 29(10):1930-1937.
39. Jeng YM, Peng SY, Lin CY and Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(6):2065-2071.
40. Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y, Zhang W, Yan S, Quan L, Bai J and Xu N. Suppression of Aurora-A oncogenic potential by c-Myc downregulation. Experimental & molecular medicine. 2010; 42(11):759-767.
41. Reiter R, Gais P, Jutting U, Steuer-Vogt MK, Pickhard A, Bink K, Rauser S, Lassmann S, Hofler H, Werner M and Walch A. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(17):5136-5141.
42. Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M, Wu X and Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012; 118(17):4346-4353.
43. Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, Knuechel R, Blaszyk H, Hartmann A and Wild PJ. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. International journal of oncology. 2007; 31(4):793-802.
44. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS and Ogino S. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009; 11(5):418-425.
45. Andarawewa KL, Erickson AC, Chou WS, Costes SV, Gascard P, Mott JD, Bissell MJ and Barcellos-Hoff MH. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer research. 2007; 67(18):8662-8670.
46. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A and Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006; 25(35):4831-4839.
47. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC and Huang CY. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PloS one. 2009; 4(4):e5052.
48. Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, Huang HY, Chen CM, Liu HL and Huang CY. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009; 28(30):2723-2737.